leadf
logo-loader
viewPolarean Imaging PLC

Polarean Imaging hails latest milestone as US regulator confirms acceptance of its new drug application

The company has developed a drug‑device combination product using hyperpolarised xenon-129 gas to enhance magnetic resonance imaging in pulmonary medicine

Polarean Imaging PLC -

Polarean Imaging PLC (LON:POLX) said it has passed another important milestone with confirmation that the US regulator has accepted its new drug application (NDA).

The US Food & Drug Administration (FDA) said the review of the company’s drug‑device combination product using hyperpolarised xenon-129 gas to enhance magnetic resonance imaging in pulmonary medicine will follow a “standard time frame”.

That means the target Prescription Drug User Fee Act or PDUFA date is October 5, 2021. This is the deadline by which the FDA must review all new drug applications and is traditionally 10 months from submission.

“The company plans to make full use of this time with regards to commercialisation and launch preparation,” Polarean said in a statement.

Chief executive Richard Hullihen added: "FDA acceptance for the filing of Polarean's NDA represents another important step forward for the Company's platform. If approved, Polarean's drug-device technology could provide a new diagnostic option for patients with pulmonary disease.”

In the same announcement, the company confirmed the planned retirement of chief operating officer Ken West, who will continue as a consultant and a non-executive director of Polarean.

“The board would like to thank Ken for his expert and untiring contributions, particularly in managing the NDA submission and its successful acceptance by FDA for review,” added Hullihen.  

“I look forward to Ken's continued support at both the board level and in relation to special projects."

Quick facts: Polarean Imaging PLC

Price: 69.5 GBX

AIM:POLX
Market: AIM
Market Cap: £113.43 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE mixed after President Trump cancelled stimulus talks

FTSE 100 reflected weaker sentiment after Donald Trump said Republicans would no longer be negotiating the stimulus package until the presidential elections are done. Tesco (LON:TSCO) hiked its dividend by 21% after a strong first half buoyed by record demand for groceries during lockdown, with...

on 7/10/20

2 min read